• The document is a regulatory filing containing the transcript of the Q2 FY27 post-results earnings call held on November 4, 2026, submitted pursuant to SEBI Listing Regulations 30 and 46(2)(oa).
  • The event was an earnings call to discuss the financial and operational performance for the quarter ended September 30, 2026 (Q2 FY27).
  • The call was held on November 4, 2026. A specific time was not mentioned in the transcript.
  • The stated purpose was to discuss the company's quarterly results and provide a strategic update.
  • The meeting was held after the earnings announcement, as it is explicitly a "post-results" call.
  • Management participants included:
  • Dr. Sharvil Patel - Managing Director
  • Mr. Ganesh Nayak - Director
  • Mr. Tushar Shroff – Chief Financial Officer
  • Mr. Arvind Bothra - Head, Investor Relations
  • Mr. Alok Garg - MD Office
  • The transcript itself was made available as an attachment to this regulatory filing. There was no mention of a presentation deck, recording, or a specific hosting location for those materials.
  • The transcript contained extensive financial data and operational highlights from the concluded quarter.

Financial Highlights from Transcript

  • Consolidated Revenue: ₹79.1 billion, up 29% Year-on-Year (YoY).
  • EBITDA Margin: 24%.
  • Reported EBITDA: ₹18.9 billion.
  • Adjusted EBITDA Margin: 25.5% (when adjusted for Saroglitazar launch investments).
  • Net Profit: ₹9.3 billion.
  • Net Debt to EBITDA: 0.62x as of September 30, 2026.
  • R&D Spend: Approximately ₹6.5 billion for the quarter.

Business Segment Performance

  • India Branded Formulations: Revenue grew 19% YoY. Secondary sales grew 20% YoY, with volume and new products contributing ~2/3 of growth. Chronic portfolio contribution stood at 56.9%.
  • International Formulations (ex-North America): Revenue of ₹10 billion, up 33% YoY.
  • North America (US & Canada): Revenue of ₹33.1 billion, up 21% YoY and 7% Quarter-on-Quarter (QoQ). Specialty products accounted for 16% of US revenue.
  • Consumer Wellness: Revenue of ₹11.2 billion, up 76% YoY. Domestic business grew 29% YoY.
  • Medical Devices: Revenue of ₹2.2 billion for the quarter.

Strategic Updates & Guidance

  • USFDA Inspections: The SEZ-II, Ahmedabad facility received 1 observation; the Moraiya facility received 5 observations. The company is addressing them.
  • US Launch Pipeline: Filed 4 ANDAs, received 12 approvals, and launched 5 products in Q2, including the first generic of Riociguat in October 2026.
  • Saroglitazar (US): Expecting a potential approval (goal date in November 2026) and planning for a commercial launch in March 2027. Annual commercial spend is estimated at ~$100 million. Meaningful revenue is expected from FY30.
  • Biosimilars: USFDA accepted the BLA for a Pembrolizumab (Keytruda) biosimilar for review.
  • Acquisitions: Rolvedon (from Assertio) is contributing to US specialty growth.
  • Outlook: The company maintains its FY27 guidance of 24%+ EBITDA margin. For the US business, it guides for high single-digit growth on a constant currency basis for FY27.

Additional Notes Section

  • The regulatory filing had one attachment: the full transcript of the earnings call.
  • Significant financial data and forward-looking statements were disclosed within the attached transcript.